Journal Watch · European Heart Journal · 2026

Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.

TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.

von Scheidt M, Adkar SS, Krefting J et al.European Heart Journal3 min readPharma relevance 75/100

DOI: 10.1093/eurheartj/ehaf602PMID: 40900105Study type: in-vitro / cell study

TL;DR

TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.

Key findings

  • Multi-omics profiling revealed up-regulation of lipid metabolism and inflammatory pathways.
  • TET2+/- macrophages exhibited increased LDLR expression and lipid uptake, linked to enhanced chromatin accessibility at the LDLR promoter.
  • These findings were confirmed in carotid plaques, which showed increased LDLR and inflammasome-related gene expression in TET2 CHIP carriers.<h4>Conclusions</h4>Clonal haematopoiesis of indeterminate potential is a predictor of mortality in CAD patients.
  • TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.

Numbers at a glance (from the abstract)

2%95%hazard ratio 1.39P < .001

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Mechanistic insights were derived from post-mortem high-sensitivity plaque proteomics (MISSION), RNA sequencing from carotid plaques (Athero-Express), monocyte-derived macrophage transcriptomes (STARNET), and CRISPR/Cas9-generated TET2+/- macrophages in vitro.<h4>Results</h4>Clonal haematopoiesis of indeterminate potential was associated with increased 3-year mortality (hazard ratio 1.39, 95% confidence interval 1.16-1.65, P < .001) in 2389 matched pairs. Mutations in TET2, ASXL1, DNMT3A, JAK2, PPM1D, SF3B1, SRSF2, and U2AF1 individually conferred higher mortality risk. In human plaques, CHIP mutations were found in lesional macrophages. TET2 CHIP carriers showed increased necrotic core size, inflammation, and reduced plaque stability.

Full abstract (original)

Background: <h4>Background and aims</h4>Clonal haematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular risk, but its prognostic relevance and mechanistic role in coronary artery disease (CAD) remains incompletely understood. This study investigated the association between CHIP and all-cause mortality in CAD and explored the cellular and molecular mechanisms, focusing on TET2 mutations.<h4>Methods</h4>Targeted deep sequencing of 13 CHIP driver genes in 8612 patients with angiographically confirmed CAD was performed. Clonal haematopoiesis of indeterminate potential carriers (variant allele frequency ≥2%) were propensity-score matched 1:1 to non-carriers. Mortality was assessed over 3 years.

What they did: Mechanistic insights were derived from post-mortem high-sensitivity plaque proteomics (MISSION), RNA sequencing from carotid plaques (Athero-Express), monocyte-derived macrophage transcriptomes (STARNET), and CRISPR/Cas9-generated TET2+/- macrophages in vitro.<h4>Results</h4>Clonal haematopoiesis of indeterminate potential was associated with increased 3-year mortality (hazard ratio 1.39, 95% confidence interval 1.16-1.65, P < .001) in 2389 matched pairs. Mutations in TET2, ASXL1, DNMT3A, JAK2, PPM1D, SF3B1, SRSF2, and U2AF1 individually conferred higher mortality risk. In human plaques, CHIP mutations were found in lesional macrophages. TET2 CHIP carriers showed increased necrotic core size, inflammation, and reduced plaque stability.

Results & conclusions: Multi-omics profiling revealed up-regulation of lipid metabolism and inflammatory pathways. TET2+/- macrophages exhibited increased LDLR expression and lipid uptake, linked to enhanced chromatin accessibility at the LDLR promoter. These findings were confirmed in carotid plaques, which showed increased LDLR and inflammasome-related gene expression in TET2 CHIP carriers.<h4>Conclusions</h4>Clonal haematopoiesis of indeterminate potential is a predictor of mortality in CAD patients. TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.

Abstract © the authors / European Heart Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/eurheartj/ehaf602 · PubMed 40900105.

Why it matters for pharma & biotech

  • Directly relevant to teams in gene editing — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: gene editing

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this European Heart Journal study find?

TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.

What type of study is this?

It is a in-vitro / cell study, published in European Heart Journal in 2026. Mechanistic insights were derived from post-mortem high-sensitivity plaque proteomics (MISSION), RNA sequencing from carotid plaques (Athero-Express), monocyte-derived macrophage transcriptomes (STARNET), and CRISPR/Cas9-generated TET2+/- macrophages in vitro.<h4>Results</h4>Clonal haematopoiesis of indeterminate potential was associated with increased 3-year mortality (hazard ratio 1.39, 95% confidence interval 1.16-1.65, P < .001) in 2389 matched pairs.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/eurheartj/ehaf602. PubMed ID: 40900105. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: von Scheidt M, Adkar SS, Krefting J et al.. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.. European Heart Journal (2026). DOI: 10.1093/eurheartj/ehaf602.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/clonal-haematopoiesis-of-indeterminate-potential-and-mortality-in-corona-haf602/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides